INCB18424: SPA received

Incyte received an SPA from FDA for the planned open-label, international Phase III RESPONSE trial to evaluate oral INCB18424 vs. best available

Read the full 220 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE